arrow
O

Olivier Bylicki

hopital d'instruction des armees sainte-anne
H指数:22
被引数:3,626

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world outcomes of caucasians with EGFR -mutated non-small-cell lung cancer treated with surgery (EXERPOS-2 GFPC study)

白人EGFR突变非小细胞肺癌患者接受手术治疗的真实世界结局(EXERPOS-2 GFPC研究)

2026-10-280
PRE
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2

NeoCOAST-2研究中可切除肺癌的循环肿瘤DNA清除与预后

Nature
IF48.5
2026-10-250
PRE
Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study

针对携带致癌基因突变型晚期非小细胞肺癌,在免疫疗法后进行靶向治疗耐受性与有效性的研究:GFPC-TOXIMAD研究

2026-08-300
OA
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study

KEYNOTE-671研究:围手术期帕博利珠单抗治疗早期非小细胞肺癌的五年结果

2026-08-210
PRE
Association of sleep-related hypoxemia with survival in patients with non-small cell lung cancer – the NEOSAS-GFPC study group

睡眠相关低氧血症与无小细胞肺癌患者生存率的相关性——NEOSAS-GFPC研究小组

CHEST
IF8.6
2026-03-090
PRE
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial

根据14基因表达谱被鉴定为分子高危的IA–IIA期非鳞状、非小细胞肺癌的辅助化疗(AIM-HIGH):一项国际、随机、III期临床试验

2025-06-240
OAAI
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
2025-05-310
OAAI
Association of sleep-related hypoxia with survival in patients with non-small cell lung cancer - the NEOSAS-GFPC study group
2024-10-300
PRE
Explore-ALK (GFPC 03-2019): A real-world prospective, multicenter study of advanced ALK rearranged non-small cell lung cancer patients

探索-ALK (GFPC 03-2019):一项真实世界前瞻性、多中心研究,探讨ALK重排的非小细胞肺癌患者

2024-09-010
PRE
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

在早期非小细胞肺癌患者中,新辅助派姆单抗加化疗后辅助派姆单抗与单独新辅助化疗的比较 (KEYNOTE-671): 一项随机,双盲,安慰剂对照的3期试验

LANCET
IF88.5
2024-09-014
PRE
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study
2024-07-015
OA
Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)

切除的EGFR突变的非小细胞肺癌: 欧洲人群的发病率和结局 (GFPC Exerpos研究)

2024-03-061
OAAI
Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
2023-10-010
PRE
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

围手术期Pembrolizumab治疗早期非小细胞肺癌

2023-08-10367
PRE